What's gone wrong at NextDC?
What's gone wrong at NextDC?
About this video
Key points:
NextDC slashes earnings guidance by around 30%, intensifying concerns over data centre funding and infrastructure costs.
Market Matters sees Goodman Group as better positioned to weather the data centre downturn, backed by its established logistics business.
Gold exposure remains modest as miners face higher input costs, while Pro Medicus remains a holding despite valuation risks linked to AI.
Australia's data centre sector is facing a major reality check, with NextDC shares plunging after a sharp downgrade to earnings guidance. James Gerrish from Market Matters says the roughly 30% reduction in earnings expectations comes amid growing concerns over the cost of building AI infrastructure and the ability of operators to fund that investment. The fallout is also weighing on contractors exposed to the sector, although Gerrish believes Goodman Group is better positioned thanks to its established logistics earnings, relatively low gearing and access to capital partners.
In energy, Woodside remains on Gerrish's watchlist rather than in his portfolio, despite a constructive share-price trend supported by higher oil and LNG prices. He warns that elevated capital expenditure could become more difficult to justify if geopolitical tensions ease and energy prices retreat. Gold miners are also contending with a pullback in bullion prices alongside higher diesel costs, creating a widening gap between companies delivering operationally and those falling short. Market Matters retains selective exposure through Evolution Mining, Bellevue Gold and Barrick, with the overall allocation reduced to around 4% to 5% across portfolios.
Pro Medicus remains a holding in Market Matters' active growth portfolio following another US contract win, this time a seven-year deal with Virtua Health. Gerrish says the company's operational execution remains strong, with continued contract wins and existing customers expanding their use of its medical imaging software. However, he acknowledges that high valuations leave growth stocks vulnerable to shifts in sentiment around bond yields and the threat posed by AI. For now, the focus remains on whether Pro Medicus can keep delivering results while the market reassesses what it is willing to pay for growth.